bupropion and Female Genital Neoplasms

bupropion has been researched along with Female Genital Neoplasms in 1 studies

Bupropion: A propiophenone-derived antidepressant and antismoking agent that inhibits the uptake of DOPAMINE.
bupropion : An aromatic ketone that is propiophenone carrying a tert-butylamino group at position 2 and a chloro substituent at position 3 on the phenyl ring.

Research

Studies (1)

Authors

Clinical Trials (1)

Trial Overview

Trial Outcomes

"Change From Baseline at 5 Weeks in Desire Subscore of the FSFI (Sexual Desire)"

"The desire subscore of the female sexual function index (FSFI) measures self-reported sexual desire. Possible scores range from 1.2 to 6, with higher scores indicating increased desire. Change score is calculated by subtracting baseline from later score, with a positive change score indicating increased desire. This measure is referred to as sexual desire in the protocol." (NCT03180294)
Timeframe: Baseline (prior to randomization) and 5 weeks from start of study treatment (within 21 days of randomization)

"Change From Baseline at 9 Weeks in the Desire Subscore of the Female Sexual Function Index (Sexual Desire)"

"The desire subscore of the female sexual function index (FSFI) measures self-reported sexual desire. Possible scores range from 1.2 to 6, with higher scores indicating increased desire. Change score is calculated by subtracting baseline from later score, with a positive change score indicating increased desire. This measure is referred to as sexual desire in the protocol." (NCT03180294)
Timeframe: Baseline (prior to randomization) and 9 weeks from start of study treatment (within 21 days of randomization)

Number of Participants With a Grade 3 or Higher Adverse Event Over the Course of the Study

Common Terminology Criteria for Adverse Events (version 4) grades adverse event severity from 1=mild to 5=death. Summary data is provided in this outcome measure.; see Adverse Events Module for specific adverse event data. (NCT03180294)
Timeframe: Adverse events were evaluated 1,2,5,7, and 9 weeks from start of study treatment (within 21 days of randomization).

"Change From Baseline in FSFI Total Score (Sexual Functioning)"

"The FSFI total score measures self-reported female sexual functioning covering the major domains arousal, satisfaction, and orgasm, and including lubrication and pain. Possible scores range from 2 to 36, with higher scores indicating better functioning. Change score is calculated by subtracting baseline from later score, with a positive change score indicating increased functioning. This measure is referred to as sexual functioning in the protocol." (NCT03180294)
Timeframe: Baseline (prior to randomization) and 5 and 9 weeks from start of treatment (within 21 days of randomization)

"Change From Baseline in the Patient Health Questionnaire (PHQ)-4 Score (Depressive Mood)"

"The PHQ-4 is a brief screening questionnaire for depression. Possible scores range from 0 to 12, with higher scores indicating more severe depression. Change score is calculated by subtracting baseline from later score, with a negative change score indicating decreased severity of depression. This measure is referred to as depressive mood in the protocol." (NCT03180294)
Timeframe: Baseline (prior to randomization) and 5 and 9 weeks from start of treatment (within 21 days of randomization)

"Change From Baseline in the PROMIS Global Satisfaction With Sex Life Subscore of Sexual Function and Satisfaction Measure (Sexual Desire and Satisfaction)"

"The PROMIS Global Satisfaction with Sex Life subscore measures self-reported global satisfaction, interest, and interference in sexual health over the past 7 days. Possible scores range from 3 to 30, with higher scores indicating more satisfaction with sex life. Change score is calculated by subtracting baseline from later score, with a positive change score indicating increased satisfaction. This score is referred to as the PROMIS sexual desire and satisfaction measure in the protocol." (NCT03180294)
Timeframe: Baseline (prior to randomization) and 5 and 9 weeks from start of study treatment (within 21 days of randomization)

Change From Baseline in the Patient Reported Outcomes Measurement Information System (PROMIS) Fatigue Score

The PROMIS fatigue score measures self-reported fatigue symptoms over the past 7 days. Possible scores range from 33.1 to 77.8, with higher scores indicating more fatigue. Change score is calculated by subtracting baseline from later score, with a positive change score indicating increased fatigue. (NCT03180294)
Timeframe: Baseline (prior to randomization) and 5 and 9 weeks from start of study treatment (within 21 days of randomization)

Number of Participants With Most Severe Response for Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) at 9 Weeks

Questions refer to the participants' experiences for the past 7 days of a given symptom in terms of frequency (never, rarely, occasionally, frequently, almost constantly), severity (none, mild, moderate, severe, very severe), interference with usual or daily activities (not at all, a little bit, somewhat, quite a bit, very much). (NCT03180294)
Timeframe: 9 weeks from start of study treatment (within 21 days of randomization).

Perception of Risk vs. Benefit at 9 Weeks

"Participants are asked, Were the benefits of this treatment greater than any side effects?" (NCT03180294)
Timeframe: 9 weeks from start of study treatment (within 21 days of randomization)

Trials

1 trial available for bupropion and Female Genital Neoplasms